CERVAVAC® Vaccine Information
CERVAVAC® stands as India’s pioneering HPV vaccine, cultivated domestically to prevent cervical cancer. This quadrivalent vaccine combats four distinct HPV variants (HPV 6, 11, 16, and 18).
- Pune’s Serum Institute of India (SII) developed the initial Indian cervical cancer vaccine, also known as the human papillomavirus (HPV) vaccine (qHPV).
- The Drugs Controller General of India (DGCI) granted approval for its use.
- This vaccine resulted from collaborative efforts between SII and the Department of Biotechnology (DBT).
Vaccine Composition Information
Each dose of 0.5 ml contains:
Human Papillomavirus type 6 L1 protein ≥ 20 mcg
Human Papillomavirus type 11 L1 protein ≥ 40 mcg
Human Papillomavirus type 16 L1 protein ≥ 40 mcg
Human Papillomavirus type 18 L1 protein ≥ 20 mcg
Al+++ ≤ 1.25 mg
Dosage Info
For vaccine recipients between 9 and 14 years old, CERVAVAC® should be administered according to a 2-dose schedule (0.5 ml at 0 and 6 months).
For vaccine recipients between 15 and 26 years old, CERVAVAC® should be administered according to a 3-dose schedule (0.5 ml at 0, 2, and 6 months).
The second dose should be administered at least one month after the first dose and the third dose should be administered at least 3 months after the second dose. All three doses should be given within a 1-year period.
